rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    NRXS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Neuraxis Inc (NRXS) Q3 2026 Earnings Call Highlights: Record Revenue, 150% Growth, and ...
      Nov 9Yahoo FinanceNRXS
      NeurAxis, Inc. Q3 2026 Earnings Call Summary
      Nov 9Yahoo FinanceNRXS
      NeurAxis (NRXS) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 9The Globe and MailNRXS
      NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth
      Nov 9Yahoo FinanceNRXS
      Earnings To Watch: Neuraxis Inc (NRXS) Q3 2026 -- GF Value Sees 48% Downside
      Nov 6Yahoo FinanceNRXS
      NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026

      CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open. The Company has scheduled a conference call for the same day, Monday, November 9, 2026, at 9:00

      Oct 27Yahoo FinanceNRXS
      Neuraxis CEO Brian Carrico buys $1,297 in company stock
      Oct 8Investing.comNRXS
      Neuraxis CFO Timothy Henrichs buys $9,375 in company stock
      Oct 8Investing.comNRXS
      Neuraxis CRO Carrico buys $1,587 in common stock
      Oct 8Investing.comNRXS
      NeurAxis at Lytham Partners fall 2026 investor conference: coverage gains By Investing.com
      Sep 29Investing.comNRXS
      NeurAxis appoints Craig Blanchard as chief commercial officer
      Sep 29Investing.comNRXS
      NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
      Sep 29Yahoo FinanceNRXS
      NeurAxis secures major insurer coverage for IB-Stim device
      Sep 16Investing.comNRXS
      NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

      Total national coverage footprint for PENFS increases to over 120 million covered livesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The c

      Sep 16Yahoo FinanceNRXS
      NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

      CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place

      Sep 16Yahoo FinanceNRXS
      Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

      NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.

      Sep 15Yahoo FinanceNRXS
      NeurAxis at iAccess Alpha conference: payer wins drive growth
      Sep 15Investing.comNRXS

      This is the newest page. Registered accounts read further back.